Thelansis

Sonic hedgehog subtype of medulloblastoma (SHH MB) with specific clinical or molecular alterations has a dismal prognosis, often leading to severe cognitive impairment in survivors. New targeted therapeutic approaches are urgently needed to improve treatment outcomes for children with SHH MB. The existing treatment, involving surgical resection, craniospinal radiation, and multi-agent chemotherapy, provides a 5-year survival rate of over 70% for newly diagnosed patients. However, this approach comes with significant side effects, including skeletal growth retardation, endocrine problems, psychiatric and social challenges, and progressive cognitive decline. SHH MB patients with specific characteristics, such as metastasis, post-operative residual disease, large-cell anaplastic histology, or MYCN amplification, continue to face a high to very high risk. ·        Medulloblastoma, the most common malignant brain tumor in children, primarily affects the cerebell...

 Sonic hedgehog subtype of medulloblastoma (SHH MB) with metastasis or specific clinical or molecular alteration has a poor prognosis. Current therapy results in long-term cognitive impairment in most survivors. Thus, a great need exists for new targeted therapeutic approaches to more effectively treat SHH MB in children. Current therapy, which combines surgical resection, craniospinal radiation, and multi-agent chemotherapy, offers a 5-year survival rate of >70% for newly diagnosed patients. However, the success of this treatment comes at a great cost, with the majority of survivors suffering skeletal growth retardation, endocrine dysfunction, psychiatric and social difficulties, and progressive cognitive impairment. SHH MB patients with tumors exhibiting either metastasis, post-operative residual disease, large-cell anaplastic histology, or MYCN amplification continue to do very poorly and are considered high to very high risk. ·        Medullob...